Table 1.
Baseline patient characteristics
| All patients | Age < 18year | Age 18 –25 year | P | |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Total | 209 | 55 (26) | 154 (74) | – |
| Age (year) | ||||
| Range | 6 –25 | 6 –17 | 18 –25 | – |
| Median | 21 | 15 | 22 | |
| Follow up (m) | ||||
| Range | 16 –135 | 24 –110 | 16 –135 | – |
| Median | 66 | 61 | 67 | |
| Sex | ||||
| M | 112 (54) | 30 (55) | 82 (53) | 0.87 |
| F | 97 (46) | 25 (45) | 72 (47) | |
| Diagnosis | ||||
| NS | 177 (85) | 47 (85) | 130 (84) | 0.83 |
| MC | 16 (8) | 5 (9) | 11 (7) | |
| LR | 1 (0.5) | 0 | 1 (1) | |
| NOS | 15 (7) | 3 (6) | 12 (8) | |
| Stage | ||||
| I | 20 (10) | 2 (4) | 18 (12) | 0.006 |
| II | 117 (56) | 26 (47) | 91 (59) | |
| III | 38 (18) | 18 (33) | 20 (13) | |
| IV | 34 (16) | 9 (16) | 25 (16) | |
| B symptoms | ||||
| Yes | 83 (40) | 20 (36) | 63 (41) | 0.55 |
| No | 126 (60) | 35 (64) | 91 (59) | |
| Bulk | ||||
| Yes | 68 (33) | 19 (35) | 49 (32) | 0.71 |
| No | 141 (67) | 36 (65) | 105 (68) | |
| Risk Group | ||||
| Limited | 78 (37) | 20 (36) | 58 (38) | 0.86 |
| Advanced | 131 (63) | 35 (64) | 96 (62) |
NS, nodular sclerosing; MC, mixed cellularity; LR, lymphocyte rich; NOS, not otherwise specified.